- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 26, 2024
Highlights
- Market Cap
- $1.52B
- Enterprise Value
- $1.46B
- EPS (TTM)
- -$3.62
- EBITDA (TTM)
- -$105.20M
- Year Range
- $16.10 - $34.65
- Target Price
- $44.00
- ROA (TTM)
- -41.58%
- ROE (TTM)
- -44.83%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AVBP Performance Chart
ArriVent BioPharma Inc. Common Stock (AVBP) is up 67.7% since the beginning of the year. At $34 per share, AVBP is trading just below its 52-week high of $35.
Loading charts...
Returns By Period
ArriVent BioPharma Inc. Common Stock (AVBP) has returned 67.69% so far this year and 47.98% over the past 12 months.
ArriVent BioPharma Inc. Common Stock
- 1D
- 3.18%
- 1M
- 26.23%
- YTD
- 67.69%
- 6M
- 51.16%
- 1Y
- 47.98%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
AVBP Monthly Returns History
Based on dividend-adjusted daily data since Jan 26, 2024, AVBP's average daily return is +0.12%, while the average monthly return is +2.05%. At this rate, an investment would double in approximately 2.8 years.
Historically, 50% of months were positive and 50% were negative. The best month was Apr 2026 with a return of +34.8%, while the worst month was Mar 2025 at -21.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, AVBP closed higher 49% of trading days. The best single day was Aug 26, 2024 with a return of +12.7%, while the worst single day was Jan 26, 2024 at -16.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 11.78% | 2.13% | 0.44% | 34.76% | -2.64% | 11.46% | 67.69% | ||||||
| 2025 | 7.13% | -17.27% | -21.69% | 14.98% | -0.05% | 2.45% | -10.38% | -2.00% | -3.50% | 1.52% | 22.48% | -12.29% | -24.47% |
| 2024 | -10.21% | -0.05% | -17.08% | -7.50% | 17.49% | -4.43% | 18.06% | 22.05% | -12.08% | 24.85% | 2.11% | -11.08% | 11.00% |
Benchmark Metrics
ArriVent BioPharma Inc. Common Stock has an annualized alpha of 13.41%, beta of 0.93, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since January 26, 2024.
- This stock participated in 135.67% of S&P 500 Index downside but only 108.47% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 13.41%
- Beta
- 0.93
- R²
- 0.07
- Upside Capture
- 108.47%
- Downside Capture
- 135.67%
Return for Risk
Risk / Return Rank
AVBP ranks 70 for risk / return — better than 70% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ArriVent BioPharma Inc. Common Stock (AVBP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AVBP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.92 | ||
| Sortino ratioReturn per unit of downside risk | -0.83 | ||
| Omega ratioGain probability vs. loss probability | 1.18 | 1.32 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 1.81 | 2.46 | -0.65 |
| Martin ratioReturn relative to average drawdown | 3.73 | 10.92 | -7.19 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ArriVent BioPharma Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ArriVent BioPharma Inc. Common Stock was 54.25%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current ArriVent BioPharma Inc. Common Stock drawdown is 5.30%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -54.25%Apr 2025 | 5mo 1d | — | 1y 7moNov 2024 - now |
2024 bear market2024 | -36.25%Apr 2024 | 2mo 29d | 3mo 24d | 6mo 23dJan 2024 - Aug 2024 |
2024 correction2024 | -19.17%Sep 2024 | 14d | 18d | 1mo 2dSep 2024 - Oct 2024 |
2024 pullback2024 | -8.80%Oct 2024 | 2d | 6d | 8dOct 2024 - Nov 2024 |
2024 pullback2024 | -6.20%Sep 2024 | 6d | 3d | 9dAug 2024 - Sep 2024 |
Drawdown Indicators
| AVBP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -54.25% | -56.78% | +2.53% |
Max Drawdown (1Y)Largest decline over 1 year | -26.66% | -9.10% | -17.56% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -5.30% | -3.21% | -2.09% |
Average DrawdownAverage peak-to-trough decline | -28.44% | -10.71% | -17.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.90% | 2.04% | +10.86% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ArriVent BioPharma Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ArriVent BioPharma Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AVBP in comparison with other companies in the Biotechnology industry. Currently, AVBP has a P/B value of 4.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AVBP
Add ArriVent BioPharma Inc. Common Stock to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AVBP